Surgical morbidity and mortality from the multicenter randomized controlled NeoRes II Trial. Standard versus prolonged time to surgery after neoadjuvant chemoradiotherapy for esophageal cancer. Ann Surg 2020; 272: 684-689.
Published: 9th February 2021
Authors: Nilsson K, Klevebro F, Rouvelas I, Lindblad M, Szabo E, Halldestam I et al.
In this study that included 249 patients, there was no difference in the rate of overall or severe complications, whether surgery was done 4-6 or 10-12 weeks after neoadjuvant chemoradiotherapy. All other perioperative outcomes were similar.Pubmed Link
You may also be interested in
Assessment of laparoscopic distal gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer. A randomized clinical trial. JAMA Surg 2019; 154: 1093-1101
Authors: Li Z, Shan F, Ying X, Zhang Y, E J-Y, Wang Y et al.
Authors: Choi IJ, Kim CG, Lee JY, Kim Y-I, Kook M-C, Park B et al.
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 2019; 393: 1948-1957.
Authors: Al-Batran S-E, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S et al.
Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial. J Clin Oncol 2018; 36: 2796-2803.
Authors: Yang H, Liu Y, Chen Y, Zhu C, Fang W, Yu Z et al.
Predictors of overall and recurrence-free survival after neoadjuvant chemotherapy for gastroesophageal adenocarcinoma: Pooled analysis of individual patient data (IPD) from randomized controlled trials (RCTs). EJSO 2017; 43: 1550-1558.
Authors: Ronellenfitsch U, Schwarzbach M, Hofheinz R, Kienle P, Nowak K, Kieser M et al.
Survival after neoadjuvant and adjuvant treatments compared to surgery alone for resectable esophageal carcinoma: a network meta-analysis. Ann Surg 2017; 265: 481-491.
Authors: Pasquali S, Yim G, Vohra R , Mocellin S, Nyanhongo D, Marriott P et al.
Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial. Lancet Oncol 2017; 18: 357-370.
Authors: Cunningham D, Stenning SP , Smyth EC, Okines AF, Allum WH, Rowley S et al.
Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. J Clin Oncol 2014; 32: 2416-2422.
Authors: Mariette C, Dahan L, Mornex F, Maillard E, Thomas P-A, Meunier B et al. et al.
Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366: 2074-2084.
Authors: Van Hagen P, Hulsof MCCM, van Lanschot JJB, Steyerberg EW, Henegouwen MIBV, Wijnhoven BPL et al. et al.
Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011; 29: 4387–4393.
Authors: Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T et al. et al.
Prospective, randomized trial comparing 5-FU/LV with or without oxaliplatin as adjuvant treatment following curative resection of gastric adenocarcinoma. Eur J Surg Oncol 2011; 37: 466–472.
Authors: Zhang X-L, Shi H-J, Cui S-Z, Tang Y-Q, Ba M-C.
Effect of early oral feeding after gastric cancer surgery: a result of randomised clinical trial. Surgery 2011; 149: 561–568.
Authors: Hur H, Kim SG, Shim JH, Song KY, Kim W, Park CH et al. et al.